JNJ | Weekly | Haru Insights

The FDA granted 510(k) clearance for the MONARCH QUEST 3 AI-powered bronchoscopy system, marking a strategic leap into robotic, AI-driven diagnostics and positioning JNJ as a key player in next-generation medical technology.
Johnson & Johnson unveiled a proposed $5.5 billion settlement to resolve nearly 76,000 talc-related ovarian cancer lawsuits, a move that could eliminate a decades-long legal overhang and signal a turning point in corporate governance and investor confidence.

JNJ’s MONARCH QUEST 3 clearance is a landmark step in establishing its dominance in AI-integrated MedTech, unlocking recurring revenue streams and validating its long-term innovation strategy.
The $5.5 billion talc settlement proposal brings unprecedented clarity, enabling JNJ to redirect capital toward R&D and shareholder returns while de-risking a decades-old legal cloud.
TREMFYA’s 71% growth and $2B quarterly run rate confirm JNJ is not just recovering from losses—it’s building a high-margin, scalable pipeline in inflammatory diseases.
Carvykti’s 49.7% YoY sales surge cements JNJ’s lead in cell therapy, proving its ability to commercialize complex biologics at scale with real market impact.
The European approval of TECVAYLI® as second-line myeloma therapy expands JNJ’s immunotherapy footprint, unlocking new patient populations and reinforcing its leadership in oncology innovation.

Johnson & Johnson (JNJ)[Tv]